GlassScriptPhysician profile
Charles W Beck
NPI 1386640233
$515.39
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $426 · 2020: $37.22 · 2021: $52.51.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $191.33 | 2019-2021 | |
| Pfizer INC. | $41.57 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $39.09 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $35.65 | 2019 | |
| Lundbeck LLC | $34.75 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $29.14 | 2019 | |
| Amgen INC. | $28.09 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.04 | 2021 | |
| Cardinal Health 200 LLC | $22.76 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $22.56 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $16.66 | 2019 | |
| Amarin Pharma, INC. | $16.56 | 2019 | |
| Astellas Pharma US INC | $14.19 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.